A phase II randomized controlled trial of tiopronin for aneurysmal subarachnoid hemorrhage.

CONCLUSIONS: The power of this study was affected by missing data. Therefore, the authors could not establish or refute an effect of tiopronin on CSF 3-AP levels. Additional observational studies investigating the role of 3-AP as a biomarker for DCI may be warranted prior to its use as a molecular target in future clinical trials.Clinical trial registration no.: NCT01095731 (ClinicalTrials.gov). PMID: 31299655 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31299655?dopt=Abstract

Source: Journal of Neurosurgery - July 11, 2019 Category: Neurosurgery Authors: Ironside N, Christophe B, Bruce S, Carpenter AM, Robison T, Yoh N, Cremers S, Landry D, Frey HP, Chen CJ, Hoh BL, Kim LJ, Claassen J, Connolly ES Tags: J Neurosurg Source Type: research